Literature DB >> 21029725

The NMR solution structure of human epidermal growth factor (hEGF) at physiological pH and its interactions with suramin.

Hsiao-Wen Huang1, Sepuru K Mohan, C Yu.   

Abstract

Human epidermal growth factor (hEGF) induces the proliferation, differentiation and survival of various cell types including tumor-derived cells. Generally, hEGF performs its biological function by binding to a specific receptor (hEGFR) on the cell surface, thereby inducing signal transduction. Suramin, a polysulfonated naphthylurea that acts as a growth factor blocker, exhibits antiproliferative activity against non-small cell lung cancer (NSCLC) cells that overexpress EGFR on the cell surface. We determined the solution structure of hEGF under physiological conditions and investigated the interaction of suramin with hEGF using isothermal titration calorimetry and NMR spectroscopy techniques. The solution structure of hEGF presented in this paper is different from the bound form of hEGF present in the crystal structure of the 2:2 EGF-EGFR complex because its C-tail contains a hydrophobic core. This conformational difference supports the hypothesis that hEGF undergoes a conformational change when it binds to hEGFR and subsequently induces signal transduction. Based on the docking structure of the hEGF-suramin complex, we demonstrated how suramin blocks hEGF by binding to its receptor binding site (the C-terminal region around Arg45) and inhibits the crucial conformational change.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029725     DOI: 10.1016/j.bbrc.2010.10.089

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  100 Years of Suramin.

Authors:  Natalie Wiedemar; Dennis A Hauser; Pascal Mäser
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Equilibrium Between Dimeric and Monomeric Forms of Human Epidermal Growth Factor is Shifted Towards Dimers in a Solution.

Authors:  Anastasia Aleksandrovna Akunevich; Vladislav Victorovich Khrustalev; Tatyana Aleksandrovna Khrustaleva; Victor Vitoldovich Poboinev; Nikolai Vladimirovich Shalygo; Aleksander Nicolaevich Stojarov; Alexander Migranovich Arutyunyan; Larisa Valentinovna Kordyukova; Yehor Gennadyevich Sapon
Journal:  Protein J       Date:  2022-03-29       Impact factor: 2.371

3.  Inactivation of epidermal growth factor by Porphyromonas gingivalis as a potential mechanism for periodontal tissue damage.

Authors:  Krzysztof Pyrc; Aleksandra Milewska; Tomasz Kantyka; Aneta Sroka; Katarzyna Maresz; Joanna Kozieł; Ky-Anh Nguyen; Jan J Enghild; Anders Dahl Knudsen; Jan Potempa
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

4.  Disulfide bonds and disorder in granulin-3: An unusual handshake between structural stability and plasticity.

Authors:  Gaurav Ghag; Christopher J Holler; Georgia Taylor; Thomas L Kukar; Vladimir N Uversky; Vijayaraghavan Rangachari
Journal:  Protein Sci       Date:  2017-06-22       Impact factor: 6.725

5.  Amlexanox Blocks the Interaction between S100A4 and Epidermal Growth Factor and Inhibits Cell Proliferation.

Authors:  Ching Chang Cho; Ruey-Hwang Chou; Chin Yu
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

6.  "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics.

Authors:  Carlos G Moscoso; Clifford J Steer
Journal:  Hepat Med       Date:  2019-09-02

7.  Development of an epidermal growth factor derivative with EGFR blocking activity.

Authors:  Clara Panosa; Francesc Tebar; Montserrat Ferrer-Batallé; Humphrey Fonge; Masaharu Seno; Raymond M Reilly; Anna Massaguer; Rafael De Llorens
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

8.  claMP Tag: a versatile inline metal-binding platform based on the metal abstraction peptide.

Authors:  Brittney J Mills; Qingxin Mu; Mary E Krause; Jennifer S Laurence
Journal:  Bioconjug Chem       Date:  2014-05-21       Impact factor: 4.774

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.